Headache Clinical Trial
Official title:
Drug and Non-Drug Treatment of Pediatric Chronic Headache
The purpose of this trial is to evaluate the efficacy of combined behavioral and pharmacological treatment on chronic daily headache in children ages 10 to 17.
Chronic daily headache (CDH)——defined as having headaches 15 or more days per month——is a
frequent and debilitating condition in children that results in severe decreased quality of
life and emotional stress. Very little is known about the most effective types of treatment
for CDH in children and adolescents. Development of effective interventions for youth with
CDH could potentially prevent the progression of a very painful and costly condition into
adulthood. Treatments combining pharmacological (drug) interventions with behavior change
have been found effective in treating adults with chronic pain, including headaches, but
have been understudied in children.
The goal of this randomized, controlled clinical trial is to determine the efficacy of
combined behavioral and drug treatment of CDH in youth ages 10 to 17. In the study,
scientists will investigate if a combination of pain coping skills training (CST) and the
drug amitriptyline (AMI)——CST-AMI——is effective in reducing headache frequency, functional
disability, and symptoms of depression. More specifically, the researchers will evaluate if
CST-AMI is superior to AMI combined with an attention control (ATT). The CST will mainly
focus on learning skills for coping with pain, and the ATT will focus on understanding
chronic headaches and lifestyle information.
Participants will be randomly assigned to one of the two treatment groups: CST-AMI or
ATT-AMI. Those assigned to CST-AMI will complete 8 weekly sessions of coping training and 2
monthly maintenance-promoting sessions. Sessions will focus on teaching biofeedback, muscle
relaxation techniques, imagery, distraction, activity pacing, problem solving, and calming
techniques, using a treatment manual developed and tested in youth with CDH. Those assigned
to ATT-AMI will receive the same amount of therapist support and attention but not the
active behavioral training. All participants will receive the study medication, AMI.
Headache frequency, functional disability, pain and headache characteristics, quality of
life, and symptoms of depression will be assessed before and after treatment, and reassessed
at 3, 6, 9, and 12 months. For participants, duration of the study——which includes treatment
and follow-up phases——lasts about 18 months. The treatment phase includes 12 study visits
and the follow-up phase includes 4 study visits.
The long-term objective of this research is to establish effective treatments for CDH in
youth that lead to significantly reduced headache frequency and functional disability.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03472872 -
A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache
|
Phase 4 | |
| Withdrawn |
NCT05410366 -
Safe Harbors in Emergency Medicine, Specific Aim 3
|
||
| Withdrawn |
NCT02866084 -
Neuromodulation Treatment of Vestibular Migraines
|
N/A | |
| Active, not recruiting |
NCT03537573 -
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
|
N/A | |
| Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
| Not yet recruiting |
NCT04352218 -
Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache
|
Phase 2 | |
| Completed |
NCT02734992 -
Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers
|
N/A | |
| Completed |
NCT01153789 -
Study of Oculomotor Dysfunction Leading to Children Vertigo
|
N/A | |
| Completed |
NCT01327118 -
Prostaglandin F2alpha in a Human Headache Model
|
N/A | |
| Not yet recruiting |
NCT00969995 -
Identification of Inflammatory Markers in Migraine Patients
|
N/A | |
| Not yet recruiting |
NCT00752921 -
Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache
|
Phase 4 | |
| Completed |
NCT00212810 -
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
|
Phase 4 | |
| Terminated |
NCT00291395 -
PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00263094 -
An End to the Yom Kippur (and Ramadan) Headache
|
N/A | |
| Completed |
NCT00135122 -
Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache
|
Phase 3 | |
| Completed |
NCT02475005 -
An Intervention to Improve Adolescent Headache Self-management
|
N/A | |
| Completed |
NCT03163901 -
The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury
|
N/A | |
| Completed |
NCT01664585 -
Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life
|
N/A | |
| Completed |
NCT04632420 -
Evaluation of Headache and Childbirth in a Chronic Pain Population
|
||
| Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|